The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Opioid-Induced Constipation Treatment Market Between 2026 And 2030?
The opioid-induced constipation treatment market size has experienced robust expansion in recent years. This market is projected to expand from $1.9 billion in 2025 to $2.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Historically, this market’s growth has been fueled by several factors, including the extensive use of opioids for managing chronic pain, the inadequate efficacy of conventional laxatives, the rising incidence of cancer-related pain, the absence of early OIC-specific treatments, and an increase in hospital admissions resulting from opioid side effects.
The market size for opioid-induced constipation treatment is anticipated to experience substantial expansion in the coming years. It is forecast to achieve $2.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.9%. This projected growth can be attributed to several factors, including an increasing demand for PAMORA-based therapies, a rise in long-term opioid prescriptions among aging populations, an amplified clinical focus on patient-centric pain management, the expansion of online and retail pharmacy access, and increased investment in drug development for gastrointestinal disorders. Significant trends for the forecast period involve the rising adoption of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC therapies that preserve analgesia, an expanding utilization of combined pharmacological and non-pharmacological treatments, an increasing emphasis on improving the quality of life for chronic pain patients, and enhanced awareness and diagnosis of opioid-induced constipation.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp
Which Major Drivers Are Influencing The Expansion Of The Opioid-Induced Constipation Treatment Market?
The increasing use of opioids for both cancer-related and non-cancer-related pain is anticipated to drive the expansion of the opioid-induced constipation treatment market in the future. Cancer pain is defined as discomfort stemming from cancer or its therapies, whereas non-cancer pain involves discomfort from conditions not linked to cancer. Opioids are prescribed for cancer and non-cancer pain primarily to manage moderate to severe discomfort efficiently. This decision takes into account the pain’s intensity and duration, the patient’s reaction to alternative treatments, and the broader objective of enhancing quality of life, all while reducing the potential for addiction and adverse effects. Treatment for opioid-induced constipation (OIC) assists individuals suffering from cancer and non-cancer pain by alleviating constipation induced by opioid use. This, in turn, boosts overall comfort, improves compliance with pain management plans, and enhances quality of life, without diminishing the effectiveness of pain relief. For example, data from November 2024, released by the US-based public health agency, the Centers for Disease Control and Prevention, indicated that in 2023, the opioid prescription dispensing rate was 37.5 per 100 persons. Additionally, in 2023, the states exhibiting the highest opioid dispensing rates per 100 individuals were Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the increased use of opioids for both cancer and non-cancer pain is stimulating the expansion of the opioid-induced constipation treatment market.
What Segment Categories Shape The Opioid-Induced Constipation Treatment Market Segment Landscape?
The opioid-induced constipation treatment market covered in this report is segmented –
1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
Which Trends Are Shaping The Opioid-Induced Constipation Treatment Market?
Major companies in the opioid-induced constipation treatment market are prioritizing innovation, such as the development of peripherally acting µ-opioid receptor antagonists (PAMORAs). These compounds focus on targeted gut receptor modulation to improve efficacy, enhance patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA operates by selectively blocking µ-opioid receptors within the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia, a distinction from traditional laxatives which do not address the underlying receptor-mediated cause of constipation. For instance, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet designed for OIC. This product provides once-daily pain relief while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering a patient-friendly alternative that combines pain control and constipation management in a single tablet.
Who Are The Companies Operating Across The Opioid-Induced Constipation Treatment Market Value Chain?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company
Get The Full Opioid-Induced Constipation Treatment Market Report:
Which Region Is The Leading Market For The Opioid-Induced Constipation Treatment Market?
North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Opioid-Induced Constipation Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company
Opioids Market Report 2026
https://www.thebusinessresearchcompany.com/report/opioids-global-market-report
Opioid Induced Constipation Treatment Market Report
Migraine Treatment Market Report
https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model